# Ruxolitinib and Steroid As First Line Therapy for Acute GVHD

> **NCT03701698** · PHASE2 · TERMINATED · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 1 (actual)

## Conditions studied

- Acute GVHD

## Interventions

- **DRUG:** Ruxolitinib Oral Tablet
- **DRUG:** Methylprednisolone

## Key facts

- **NCT ID:** NCT03701698
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-01
- **Primary completion:** 2024-09-20
- **Final completion:** 2024-09-20
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Participants recruitment failure
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03701698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03701698, "Ruxolitinib and Steroid As First Line Therapy for Acute GVHD". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03701698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*